October 3, 2007 - Avid Radiopharmaceuticals Inc., a product-focused molecular imaging company, announced today that enrollment has begun in a proof-of-concept phase I clinical trial investigating Avid’s development compound 18F-AV-133 for imaging patients with movement disorders, including Parkinson’s Disease (PD) and essential tremor and dementias, including Dementia with Lewy Bodies (DLB) and Alzheimer’s Disease (AD).
The compound, used with positron emission tomography (PET) imaging, targets vesicular monoamine transporters (VMAT2) in the brain and may enable more accurate and earlier diagnosis of neurodegenerative diseases. This new imaging compound may thus lead to improved disease management for patients and their caregivers. The study will be initially conducted at the University of Michigan and will involve 30 patients.
Avid’s 18F-AV-133 compound may also be useful for improved management of Alzheimer’s Disease (AD) because up to 25 percent of AD patients also have a component of PD or DLB. The goal of this initial trial is to determine whether 18F-AV-133 PET imaging can detect losses in nigrostriatal neurons in the brains of patients with AD, PD and DLB. Patients with overlapping symptoms and disease pathology are often misdiagnosed today.
The VMAT2 study represents the second clinical stage program in Avid’s development pipeline. The company, founded in 2004, is currently conducting a phase one clinical trial of its PET amyloid imaging compound for early detection of AD.
For more information: www.avidrp.com
July 09, 2024 
